Can biomarkers identify women at increased stroke risk? The Women's Health Initiative hormone trials

PLoS Clinical Trials

Volumn 2, Issue 6, 2007, Pages

  Kooperbergl, Charles ^a   Cushman, Mary ^b   Hsia, Judith ^c   Robinson, Jennifer G ^d   Aragaki, Aaron K ^a   Lynch, John K ^e   Baird, Alison E ^e   Johnson, Karen C ^f   Kuller, Lewis H ^g   Beresford, Shirley A A ^h   Rodriguez, Beatriz ⁱ  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTROGEN RECEPTOR; FIBRINOGEN; GELATINASE B; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MONOTHERAPY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STROKE; UTERUS; WOMEN'S HEALTH;

EID: 34250757702     PISSN: None     EISSN: 15555887     Source Type: Journal    
DOI: 10.1371/journal.pctr.0020028     Document Type: Article

References (22)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
2. Anderson GL, Limacher M, Assaf AR, Bassford SA, Black H, et al. (2004) Effects of conjugated equine estrogen on postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712.
3. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, et al. (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 289: 2673-2684.
4. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, et al. (2006) Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113: 2425-2434.
5. Women's Health Initiative Study Group (1998) Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19: 61-109.
6. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, et al. (2003) The Women's Health Initiative recruitment methods and results. Ann Epidemiol 13: S18-S77.
7. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, et al. (2003) The Women's Health Initiative postmenopausal hormone trials: Overview and baseline characteristics of participants. Ann Epidemiol 13: S78-S86.
8. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, et al. (2003) Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 13: S122-S128.
9. Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, et al. (1999) Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19: 493-498.
10. Macy EM, Meilahn EN, Declerck PJ, Tracy RP (1993) Sample preparation for plasma measurement of plaminogen activator inhibitor-1 antigen in large population studies. Arch Pathol Lab Med 117: 67-70.
11. Hastie TJ, Tibshirani RJ (1990) Generalized Additive Models. New York: Chapman and Hall, 336 p.
12. Freedman LS, Graubard BI, Schatzkin A (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11: 167-178.
13. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, et al. (2003) Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Stroke 34: 623-631.
14. Psaty BM, Anderson M, Kronmal RA, Tracy RP, Orchard T, et al. (2004) The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc 52: 1639-1647.
15. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, et al. (2005) Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke 36: 768-772.
16. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979.
17. Zhang D, Sun M, Samols D, Kushner I (1996) STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 271: 9503-9509.
18. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, et al. (1999) Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 100: 717-722.
19. Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, et al. (2006) Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Am J Med 119: 167.e1-167.e8.
20. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, et al. (1997) Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336: 683-690.
21. Cote R, Wolfson C, Solymoss S, Mackey A, Leclerc JR, et al. (2000) Hemostatic markers in patients at risk of cerebral ischemia. Stroke 31: 1856-1862.
22. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, et al. (2005) Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly study. Circulation 112: 3080-3087.